SRTA: Clinical-led growth and record free cash flow support reiterated targets and capital returns

What happened

Q3 revenue rose 50.3% year over year and Adjusted EBITDA reached $9.6 million. Free cash flow hit a record $8.6 million. The company reiterated its FY2026 guidance, with clinical growth and acquisitions supporting its 2027 targets.

Confirmed

Global impact / market context

Record free cash flow means cash left after running and investing in the business. That cash can fund clinical programs and acquisitions without as much outside financing, reducing reliance on borrowed money and supporting the reiterated 2027 targets.

Analyst inference

For a medical company, revenue growth of 50.3% alongside positive free cash flow suggests scaling operations rather than just spending. Investors weighing the reiterated guidance will focus on whether clinical spending and deal costs keep pressuring near-term profit.

Analyst inference

What to watch

1. Q3 revenue grew 50.3% year over year, while Adjusted EBITDA was $9.6 million and free cash flow was a record $8.6 million, showing strong cash generation. Confirmed
2. Watch whether management's reiterated FY2026 guidance is met, since the article states the guidance was repeated rather than changed, leaving execution against it as the key test. Proposed
3. Track spending on clinical programs and acquisitions, because those costs could absorb cash and affect how much free cash flow is left to support capital returns. Analyst inference

Evidence

• Original source link unavailable